Table 1.
Clinical and CyCIF antibodies used in the study.
| No. | Target | AB name | Vendor | Cat. no. | Performance by CyCIF | Notes | Selected for final panel? |
|---|---|---|---|---|---|---|---|
| ab1 | AR | AR (AR441) | Thermo Fisher | TF-MA5-13426 | * | Clinical | n/a |
| ab2 | AR | AR-555 | CST | 8956 | * | CyCIF | N |
| ab3 | AR | AR-647 | Abcam | AB194195 | *** | CyCIF | Y |
| ab1 | ER | ER (sp1) | Abcam | ab16660 | *** | Clinical | n/a |
| ab2 | ER | ER-PE | CST | 74244 | *** | CyCIF | Y |
| ab3 | ER | ER-568 | Abcam | ab207261 | ** | CyCIF | N |
| ab4 | ER | ER-647 | Abcam | ab205851 | ** | CyCIF | N |
| ab1 | HER2 | HER2 (sp3) | Thermo Fisher | TF-MA5-14509 | *** | Clinical | n/a |
| ab2 | HER2 | HER2-488 | R&D | RD-FAB9589G | ** | CyCIF | N |
| ab3 | HER2 | HER2-PE | CST | 98710 | *** | CyCIF | Y |
| ab4 | HER2 | HER2-647(BL) | Biolegend | BL324412 | * | CyCIF | N |
| ab5 | HER2 | HER2-647 | Abcam | ab225510 | *** | CyCIF | Y |
| ab6 | HER2 | HER2-647(RD) | R&D | RD-FAB1129R | ** | CyCIF | N |
| ab1 | p53 | p53 (DO-7) | Abcam | Dako_M7001 | *** | Clinical | n/a |
| ab2 | p53 | p53-488 | CST | 5429 | * | CyCIF | N |
| ab3 | p53 | p53-647 | Abcam | ab224942 | *** | CyCIF | Y |
| ab4 | p53 | anti-p53 | Abcam | ab32389 | *** | unconjugated | n/a |
| ab1 | PR | PR (PgR636) | DAKO | Dako-M3569 | *** | Clinical | n/a |
| ab2 | PR | PR-488 | Abcam | ab199224 | *** | CyCIF | Y |
| ab3 | PR | PR-647 | Abcam | ab199455 | *** | CyCIF | Y |
| ab4 | PR | PR-660 | Ebioscience | EB50-9764-80 | ** | CyCIF | N |
| ab5 | PR | PR-PE | CST | 23353 | ** | CyCIF | N |
Clinical antibodies are indicated as ab1. Qualified CyCIF antibodies are indicated by “Y” in the last column. Performance by CyCIF is ranked from 1 asterisk to 3 asterisks as shown.
*no signal.
**signal in some tissues, but no concordance with clinical antibodies.
***strong signal & show agreement with clinical antibodies.